

Namzaric[®] (memantine/donepezil) – First-time generic

- On January 23, 2025, [Amneal launched](#) an [AB-rated](#) generic version of AbbVie's [Namzaric \(memantine/donepezil\)](#) 14 mg/10 mg and 28 mg/10 mg extended-release capsules.
 - Amneal has been granted 180 days of generic exclusivity for its generic Namzaric.
 - ANI Pharmaceuticals received FDA approval of an [AB-rated](#) generic version of Namzaric 21 mg/10 mg extended-release capsules on December 15, 2023. Launch is pending.
 - Namzaric is also available as a 7 mg/10 mg extended-release capsule.
- Namzaric is approved for the treatment of moderate to severe dementia of the Alzheimer's type in patients stabilized on 10 mg of donepezil hydrochloride once daily.
- According to IQVIA[®], Namzaric had annual U.S. sales of \$88 million as of November 2024.